Aquestive Therapeutics (AQST)
(Delayed Data from NSDQ)
$5.52 USD
+0.03 (0.55%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $5.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$5.52 USD
+0.03 (0.55%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $5.52 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth C Momentum F VGM
Zacks News
Aquestive Therapeutics (AQST): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Top Ranked Momentum Stocks to Buy for April 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th
Company News for Mar 13, 2020
by Zacks Equity Research
Companies In The News Are: POAI, APT, AQST, TACO
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -6.67% and 4.08%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Top Ranked Momentum Stocks to Buy for December 9th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, December 9th
Company News For Nov 26, 2019
by Zacks Equity Research
Companies In The News Are:
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy
by Zacks Equity Research
Aquestive Therapeutics (AQST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Company News for Nov 7, 2019
by Zacks Equity Research
Companies In The News Are: WW, VNTR, PLT, AQST
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 30.77% and 20.39%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -22.39% and 6.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Aquestive Therapeutics (AQST) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Aquestive Therapeutics (AQST) Upgraded to Buy: Here's Why
by Zacks Equity Research
Aquestive Therapeutics (AQST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).